Navigation Links
NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Date:3/24/2008

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204.

The single-center study, which NuRx expects to complete in the fourth quarter of this year, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company's first drug candidate in clinical trials.

"Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to pursue the development of this compound as a treatment for both indications. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. Th
'/>"/>

SOURCE NuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ordingtoMillenniumResearchGroup(MRG),theglobalauth...ly$3billionUSmarketfortraumafixationdeviceswillcon...erecenteconomicslowdown.MRG,s USMarketsforTraumaDe...hlydynamicoverthenextfiveyears,withcompetitorsintr...gmentsofthetraumafixationmarket,fuelingmarketgrowt...
(Date:11/25/2009)...empraPharmaceuticalsInc.todayannouncedthatPrabhava...lpresentatthePiperJaffray21stAnnualHealthCareConfe...ceHotelinNewYorkCity.Dr.Fernandeswillprovideanover...ramsforthetreatmentofdrug-resistantpathogensinclud...Foundedin2006,CempraPharmaceuticalsisaprivately-he...
(Date:11/25/2009)...ker.comannouncesthatanewmarketresearchreportisavai...-USMarketTrends&Analysis http://www.reportlin...ket-Trends--Analysis.html ,, TheUSintranasaldr...icapplicationsfromthedeliveryofconventionallocalth...ugs.Thefutureofthetechnologyhingesontotheeffective...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 56843 1Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 56843 2Obama Speech Heralds Prevention Power of Screening Tests Like Colonoscopy 56843 3H1N1 Swine Flu Preparedness Uncertainty Results in Higher Business Disruption Risk 56840 1H1N1 Swine Flu Preparedness Uncertainty Results in Higher Business Disruption Risk 56840 2Most Pharmaceutical Companies Receive Poor Grades on HIV AIDS Drug Development Innovation According to AIDS Treatment Activist Coalition Report Card 56837 1Most Pharmaceutical Companies Receive Poor Grades on HIV AIDS Drug Development Innovation According to AIDS Treatment Activist Coalition Report Card 56837 2Most Pharmaceutical Companies Receive Poor Grades on HIV AIDS Drug Development Innovation According to AIDS Treatment Activist Coalition Report Card 56837 3
...uced risk of death by 13% (P=0.08), despite inclus...mara therapy , , - In a separate censored ana...o Femara, reduction in risk of death was 19% , ...IG 1-98 trial reinforces starting with Femara as t... , EAST HANOVER, N.J., Dec. 11 New long-term d...
...cember 11 AFFiRiS has started,pre-clinical develo... as,PD01, can be used to target a specific protein...s degenerative neurological disease. Excellent pro...ed the company to file a patent,application and pr...tive,results from external assessments impelled th...
Other Medicine Technology:Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 2Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 3Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 4Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 5Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 6Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 7Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery 8AFFiRiS Begins Development of a Parkinson's Vaccine 2AFFiRiS Begins Development of a Parkinson's Vaccine 3
(Date:11/25/2009)...mice, disks placed under the skin kill tumor cells...althDay News) -- A cancer vaccine delivered in a f...in mice, a new study reports. , The method uses...are loaded with tumor-specific antigens and implan...to attack tumors. The Harvard University scientist...
(Date:11/25/2009)... BioSpace.com, the premier r...unveiled the third edition of the BioForest™... Englewood, CO (Vocus) November 25, 2009 --...ce careers and information, unveiled the third edi...morning., , , , ,This regional campaign is a prom...
(Date:11/25/2009)..., SALTLAKECITY,Nov.25/PRNewswire/--dazzlesmile,...C www.optimalhealthscience.com havefileda67-pagefe...azoogle.com,Inc.,JesseWillms,FarendServicesLimited...ththeUnitedStatesDistrictCourtfortheDistrictofUtah...gofdazzlesmile(TM)brandedteethwhiteningproducts,vi...
(Date:11/25/2009)... HOUSTON - Two signaling pathways essential to nor... epidermal growth factor receptor (EGFR) pathways ...asion and metastasis, researchers from The Univers...n the Nov. 25 issue of Molecular Cell . , This ...naling components known to correlate with invasive...
(Date:11/25/2009)...This press release is available in French . , ,...nologies are about to enter the marketplace, thank...imited Partnership (Univalor) and Cognitive Sensin... based in Montreal. , Univalor, which commercial... its affiliated institutions, and CSI have announc...
Breaking Medicine News(10 mins):Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2
... 40%, to 56,000 new cases annually, CDC researcher...) -- The number of Americans newly infected with H...at was previously assumed, U.S.health officials ha..., Using the new method, researchers at the U.S. Ce...
...aw Firm Offers Assistance, Information to People A... Houston, TX (PRWEB) August 2, 2008 ...leman announce the launch of a http://www.tysabri...ysabri, a drug used to treat multiple sclerosis (M...
... new infections in 2006,follows nearly two-year de...w HIV infection,figures scheduled to be released o...and Prevention (CDC) are expected to increase the ...n ongoing,increase in the annual estimated infecti...
...Nasdaq: GXDX ), a specialized laboratory services... and Laurence R. McCarthy, Ph.D. to its Board of,D...am has been elected to,serve as a Class I director... elected to serve as a Class II director of,Genopt...
...ogram launched locally to help people manage the d...hospital admissions among participants. , The fir...s & Balances encourages people with diabetes to co...-cholesterol, an eye exam, and screening for kidne...
...ke reactions to nonionic iodinated contrast materi...nd can be treated safely with commonly used medica...earchers at the University of Michigan Hospitals i...st material to patients and some of these reaction...
Other Medicine News:Health News:Number of New U.S. HIV Infections Gets Revised Upwards 2Health News:Tysabri Lawyers Pulaski & Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects 2Health News:New HIV Infection Figures from CDC to be Announced on Aug. 3 Underscore Need for National AIDS Strategy for the U.S. 2Health News:Genoptix Announces the Addition of New Members to Board of Directors 2Health News:Genoptix Announces the Addition of New Members to Board of Directors 3Health News:Innovative diabetes program in Bloomington-Normal, Ill., a success 2Health News:Allergic-like reactions to iodinated contrast material treated safely with commonly used medications 2
Sterile Coil Packed Pediatric Suction Catheters with SAFE-T-VAC Valve
Sterile Suction Catheters without Control Valve
Sterile Single Loop Suction Catheters with TOUCH-TROL Valve
Catheter Suction 14FR Sterile W/Control Valve
Medicine Products: